Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 06 2022
Historique:
received: 03 03 2021
accepted: 31 05 2022
entrez: 8 6 2022
pubmed: 9 6 2022
medline: 11 6 2022
Statut: epublish

Résumé

Tγδ large granular lymphocyte leukemia (Tγδ LGLL) is a rare lymphoproliferative disease, scantily described in literature. A deep-analysis, in an initial cohort of 9 Tγδ LGLL compared to 23 healthy controls, shows that Tγδ LGLL dominant clonotypes are mainly public and exhibit different V-(D)-J γ/δ usage between patients with symptomatic and indolent Tγδ neoplasm. Moreover, some clonotypes share the same rearranged sequence. Data obtained in an enlarged cohort (n = 36) indicate the importance of a combined evaluation of immunophenotype and STAT mutational profile for the correct management of patients with Tγδ cell expansions. In fact, we observe an association between Vδ2/Vγ9 clonality and indolent course, while Vδ2/Vγ9 negativity correlates with symptomatic disease. Moreover, the 7 patients with STAT3 mutations have neutropenia and a CD56-/Vδ2- phenotype, and the 3 cases with STAT5B mutations display an asymptomatic clinical course and CD56/Vδ2 expression. All these data indicate that biological characterization is needed for Tγδ-cell neoplasm definition.

Identifiants

pubmed: 35676278
doi: 10.1038/s41467-022-31015-x
pii: 10.1038/s41467-022-31015-x
pmc: PMC9177852
doi:

Substances chimiques

Receptors, Antigen, T-Cell, gamma-delta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3298

Informations de copyright

© 2022. The Author(s).

Références

Haematologica. 2020 May;105(5):1351-1360
pubmed: 31467122
Front Immunol. 2018 Jul 02;9:1501
pubmed: 30013562
Cytometry B Clin Cytom. 2005 Sep;67(1):6-12
pubmed: 15973700
PLoS Comput Biol. 2015 Nov 25;11(11):e1004503
pubmed: 26606115
Ann Diagn Pathol. 2017 Feb;26:16-22
pubmed: 28038706
Front Oncol. 2020 Feb 18;10:152
pubmed: 32133291
Nat Commun. 2017 Mar 01;8:14760
pubmed: 28248310
Blood Cancer J. 2022 Feb 24;12(2):31
pubmed: 35210405
Cell Immunol. 2015 Jul;296(1):22-30
pubmed: 25769734
J Immunol. 2019 Mar 15;202(6):1859-1870
pubmed: 30710048
Am J Clin Pathol. 2015 Oct;144(4):607-19
pubmed: 26386082
Nature. 1986 Nov 20-26;324(6094):268-70
pubmed: 3491323
Leukemia. 2020 Apr;34(4):1116-1124
pubmed: 31740810
N Engl J Med. 2012 May 17;366(20):1905-13
pubmed: 22591296
Blood Adv. 2019 Mar 26;3(6):917-921
pubmed: 30898763
Cells. 2020 Mar 16;9(3):
pubmed: 32188103
J Immunol. 2001 Dec 15;167(12):6773-9
pubmed: 11739492
Blood. 1994 Oct 1;84(7):2315-21
pubmed: 7522625
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Nat Immunol. 2018 Dec;19(12):1352-1365
pubmed: 30420626
Haematologica. 2015 Jan;100(1):91-9
pubmed: 25281507
Am J Clin Pathol. 2011 Aug;136(2):289-99
pubmed: 21757603
Blood. 2017 Mar 2;129(9):1082-1094
pubmed: 28115367
Am J Surg Pathol. 2017 Jan;41(1):82-93
pubmed: 27755009
Leukemia. 2006 Mar;20(3):505-13
pubmed: 16437145
Oncotarget. 2017 Jun 27;8(37):61876-61889
pubmed: 28977911
Clin Chem. 2020 Sep 1;66(9):1228-1237
pubmed: 32814950
Front Immunol. 2018 Jul 11;9:1601
pubmed: 30050536
Cancers (Basel). 2020 Nov 25;12(12):
pubmed: 33255665
Nat Immunol. 2019 Feb;20(2):121-128
pubmed: 30664765
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):610-3
pubmed: 23800602
Leukemia. 2014 Nov;28(11):2244-8
pubmed: 24947020
Sci Rep. 2018 Mar 2;8(1):3956
pubmed: 29500378
J Exp Med. 2010 Apr 12;207(4):807-21
pubmed: 20368575
Cancer Discov. 2017 Apr;7(4):369-379
pubmed: 28122867
Leuk Res. 2008 Jan;32(1):45-8
pubmed: 17544120
Haematologica. 2009 Oct;94(10):1341-5
pubmed: 19794080
Blood. 2016 Nov 17;128(20):2465-2468
pubmed: 27697773
J Leukoc Biol. 2011 Jan;89(1):75-84
pubmed: 20952657
Blood. 2013 Dec 12;122(25):4077-85
pubmed: 24149287
Blood. 1988 Apr;71(4):923-31
pubmed: 2965605
Blood. 2013 May 30;121(22):4541-50
pubmed: 23596048
Leukemia. 2006 May;20(5):883-6
pubmed: 16525496
Stem Cells Int. 2019 Dec 6;2019:6348060
pubmed: 31885619
Indian J Med Res. 2011 Sep;134:356-61
pubmed: 21985819
Front Immunol. 2018 Mar 06;9:448
pubmed: 29559980
Br J Haematol. 2020 Sep;190(5):e301-e304
pubmed: 32478405
J Immunol. 2008 Oct 1;181(7):4471-84
pubmed: 18802050

Auteurs

Antonella Teramo (A)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Andrea Binatti (A)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Elena Ciabatti (E)

Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.

Gianluca Schiavoni (G)

Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.

Giulia Tarrini (G)

Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.

Gregorio Barilà (G)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Giulia Calabretto (G)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Cristina Vicenzetto (C)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Vanessa Rebecca Gasparini (VR)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Monica Facco (M)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Iacopo Petrini (I)

Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Roberto Grossi (R)

Department of Computer Science, University of Pisa, Pisa, Italy.

Nadia Pisanti (N)

Department of Computer Science, University of Pisa, Pisa, Italy.

Stefania Bortoluzzi (S)

Department of Molecular Medicine, University of Padova, Padova, Italy.
CRIBI Biotechnology Center, University of Padova, Padova, Italy.

Brunangelo Falini (B)

Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.

Enrico Tiacci (E)

Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.

Sara Galimberti (S)

Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.

Gianpietro Semenzato (G)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy. g.semenzato@unipd.it.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy. g.semenzato@unipd.it.

Renato Zambello (R)

Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy. r.zambello@unipd.it.
Veneto Institute of Molecular Medicine (VIMM), Padova, Italy. r.zambello@unipd.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH